October 30, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG AND NON-SWOG INSTITUTIONS

TO SWOG-COORDINATED NCTN TRIALS

BY COMMITTEE

83% of Calendar Year is Past

Committee Annual
Base
Accrual²		 Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
BREAST 472 1015 214% 840 543 988
ERLYTX 54 60 112% 50 6 58
GI 100 102 102% 84 2 99
GU 256 308 120% 255 52 298
LEUK 354 764 215% 632 410 748
LUNG 817 554 68% 458 -263 555
LYMPH 181 372 205% 308 191 356
MELAN 364 0 0% 0 -364 0
MMYEL 192 106 55% 88 -86 99
MULT 25 42 169% 35 17 47
Total 2815 3323   2750 508 3248

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 30, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG AND NON-SWOG INSTITUTIONS

TO SWOG-COORDINATED NCORP TRIALS

BY COMMITTEE

83% of Calendar Year is Past

Committee Annual
Base
Accrual²		 Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
CCD 578 207 36% 171 -371 195
PEOLC 52 29 56% 24 -23 55
PREV 169 0 0% 0 -169 0
SXQOL 958 598 62% 495 -360 582
Total 1757 834   690 -923 832

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 30, 2026 Page

CURRENT AND PROJECTED ACCRUAL

BY SWOG AND NON-SWOG INSTITUTIONS

TO SWOG CTP TRIALS

BY STUDY

83% of Calendar Year is Past

Committee Study Projected
2026
Accrual		 2026
Accrual
to date		 Accrual
Last
12 Months
ERLYTX 21CTP.HN01 15 12 12
LEUK 21CTP.LEUK01 11 9 9
Total   26 21 21

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 30, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG INSTITUTIONS

TO ANY NCTN TRIAL

BY COMMITTEE

83% of Calendar Year is Past

Committee Annual Base Accrual² Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
BREAST 352 697 198% 577 345 695
ERLYTX 42 47 111% 39 5 45
GI 157 138 87% 114 -19 133
GU 399 317 79% 262 -82 308
LEUK 182 344 189% 285 162 346
LUNG 551 365 66% 302 -186 363
LYMPH 173 289 166% 239 116 279
MELAN 228 7 3% 6 -221 8
MMYEL 135 68 50% 56 -67 64
MULT 14 18 132% 15 4 19
OTHER 57 62 108% 51 5 61
Total 2290 2352   1946 62 2321

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 30, 2026 Page

CURRENT AND PROJECTED ACCRUAL¹

BY SWOG INSTITUTIONS

TO ANY NCORP TRIAL

BY COMMITTEE

83% of Calendar Year is Past

Committee Annual Base Accrual² Projected
2026
Accrual		 2026
Projected
Percentage
of Base Accrual		 2026
Accrual
to date		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months
CCD 534 160 30% 132 -374 156
GI 0 1 .% 1 1 1
PEOLC 37 27 72% 22 -10 47
PREV 341 220 64% 182 -121 225
SXQOL 665 492 74% 407 -173 474
Total 1577 900   744 -677 903

¹ Includes Accrual to Screen Only Studies

² Average Annual Accrual Over Three Prior Calendar Years

October 30, 2026 Page

SWOG OPEN AND TEMPORARILY CLOSED NCTN STUDIES

Comm. Phase Study Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure		 Proj.
Study
Duration
(Years)
BREAST III S2206: Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva 10/30/2023 36 433 960 11.5 Jul-2030 6.7
    S2212: Breast, TNBC, Neoadj Chemo + Pembro 07/21/2023 39 1773 2400 68.8 Jul-2027 4.0
    S2511: Brst, de novo StgIV oligo, locoreg tx vs SOC 08/18/2026 2 0 534      
ERLYTX II SN2426: cSCC, IC Met/Inop, Amivantamab v Cetuximab 01/28/2026 9 12 86 1.3 May-2031 5.3
  II-III S2012: Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo 12/02/2021 58 171 189 3.0 Apr-2027 5.4
  III S2505: Sarcoma, Stg II-IIIB, Surg + Short vs Std RT 07/06/2026 3 0 296 0.3 > 15 Yrs > 15 Yrs
GI II S2104: Panc,Resect High-risk,Postop Adj Chemo vs Obs 10/14/2021 60 113 154 3.2 Oct-2027 6.0
  II-III S2303: Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo 05/06/2024 29 128 224 5.8 Feb-2028 3.8
  III S2433: PANC, KRAS WT, Met, SOC Chemo +/- Panitumumab 12/26/2025 10 1 94 0.2 > 15 Yrs > 15 Yrs
GU II S2210: Pros, High Risk, BRCA, Neoadj Carbo 08/14/2023 38 7 44 0.2 > 15 Yrs > 15 Yrs
    S2427: Blad, MIBC, RT + Pembrolizumab 09/04/2025 13 66 111 9.2 Feb-2027 1.5
  III S1802: Pros, Stg IV, SST ± Surg/RT to Primary Tum 09/17/2018 97 1064 1273 8.3 Nov-2028 10.2
    S1931: RENAL, Stg IV, IO + Nephrectomy. vs IO Only 11/16/2020 71 167 336 3.0 Jun-2031 10.6
    S2312: Pros, MCRPC, Cab +/- Carb 09/03/2024 25 76 500 4.0 Aug-2035 11.0
    S2419: Renal, adv clear cell, IO +/- Biotx, BIOFRONT 04/22/2026 6 44 718 7.3 May-2034 8.1
LEUK II MM1OA-S03: AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena 04/01/2025 18 32 102 4.0 Mar-2028 3.0
    MM1OA-S04: MyeloMATCH: AML, ASTX727 + Ven (28D v 14D) 07/22/2026 3 1 126 0.3 > 15 Yrs > 15 Yrs
    MM1YA-S01: AML, High Risk, Age <60, 7+3 vs experimental 05/16/2024 29 97 335 4.5 Feb-2031 6.8
    S2507: ALL/ALAL, KMT2A-trans, Blina +/- Revumenib 09/22/2026 1 0 90      
  III S1925: CLL/SLL, Newly Dx HR, Early vs Delayed V+O 12/14/2020 70 214 247 4.7 May-2027 6.5
    S2504: Richter Trans., Untreated, R-CHOP +/- Pirto 06/01/2026 4 2 102 0.4 > 15 Yrs > 15 Yrs
  OTHER MYELOMATCH: MSRP for the NCI myeloMATCH Clinical Trials 05/16/2024 29 1381   52.2 .- . .
LUNG II S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu 04/03/2023 42 29 44 0.7 Aug-2028 5.4
    S1900K: MET Exon 14: Tepotinib +/- Ramucirumab 12/18/2023 34 32 56 1.2 Jun-2028 4.5
    S1900N: AGAs: SG alone, I alone, or SG + I 08/03/2026 2 2 117      
    S2409: ESCLC, Durvalumab +/- Biomarker Directed Tx 09/08/2025 13 19 900 2.5 > 15 Yrs > 15 Yrs
  II-III S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab 04/28/2025 18 150 378 9.7 Sep-2028 3.4
  III S2414: NSCLC, Stg II-IIIB, Durva vs Surveillance 03/14/2025 19 15 306 1.2 > 15 Yrs > 15 Yrs
  OTHER LUNGMAP: NSCLC, Adv, Master 01/28/2019 93 4161   29.3 .- . .
LYMPH II S2114: NHL, Rel/Ref, CD19 CAR-T +/- Consolidation 02/23/2023 44 260 396 7.8 Mar-2028 5.1
    S2207: LBCL, Transplant Inelig, Targeted Tx + Tafa 06/30/2023 40 44 173 0.8 Aug-2039 16.2
    S2506: NHL, R/R MZL, Mozun +/- Zanu or Pola 08/18/2026 2 1 138      
  III S2308: FL, LTB, Mosunetuzumab vs Rituximab 08/01/2024 26 452 600 23.2 Apr-2027 2.7
MMYEL II S2005: WM, Prev. Untreated, I/R or Z v V/R 06/24/2021 64 46 92 3.2 Dec-2027 6.5
  III S1803: MM, Maintenance, Len vs Len/Dara 06/27/2019 88 1338 1100 0.0    
    S2209: MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 05/30/2023 41 149 510 3.5 May-2035 12.0
    S2213: AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 12/01/2023 34 56 142 2.5 Aug-2029 5.7
MULT II S2101: Melan or HNSCC, Adv, Cabo + Nivo 10/14/2022 48 111 220 3.0 Oct-2029 7.0
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

October 30, 2026 Page

SWOG OPEN AND TEMPORARILY CLOSED NCORP STUDIES

Comm. Phase Study Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure		 Proj.
Study
Duration
(Years)
CCD III S1703: Met Breast, STM-monitoring v Usual Care 07/16/2018 99 477 498 3.3 Apr-2027 8.8
    S2417CD: Colrec Surv, Follow-up w/ CTAC site 08/04/2025 14 143 654 13.7 Nov-2029 4.3
    S2424CD: A-PACT vs SOC for GOC communication 06/01/2026 4 10 1000 2.0 > 15 Yrs > 15 Yrs
PEOLC III S1501: Breast Stg IV, Card Tox Obs and w/ Carvedilol 09/15/2017 109 403 491 2.3 Nov-2029 12.2
    S2408: Panc Fistula Prevention, Lanreotide 02/14/2025   63 274      
SXQOL III S2205: ICE COMPRESS: Reduction of CIPN from Taxanes 03/16/2023 43 696 777 16.5 Feb-2027 4.0
  OTHER S2013: I-CHECKIT: ICI toxicity risk prediction study 08/16/2021 62 2683 3609 33.7 Jan-2029 7.5
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

October 30, 2026 Page

SWOG OPEN AND TEMPORARILY CLOSED CTP STUDIES

Comm. Phase Study Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure		 Proj.
Study
Duration
(Years)
ERLYTX II 21CTP.HN01: HN, Recur/Met, Amivantamab + Chemo 03/05/2026 7 12 50 1.5 Nov-2028 2.7
LEUK II 21CTP.LEUK01: ALL, Ph+, Asciminib, Dasatinib and Prednisone 12/11/2025 10 9 55 1.3 Aug-2029 3.7
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.